Registry Study on the Multidimensional Assessment of Disease Course and Quality of Life in Patients with Epilepsy and Psychogenic Nonepileptic Seizures in Southwestern Germany

Registry Study on the Multidimensional Assessment of Disease Course and Quality of Life in Patients with Epilepsy and Psychogenic Nonepileptic Seizures in Southwestern Germany - EPISWED-REG

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00041100

Enrollment

5000

Registered

2026-07-27

Start date

2025-10-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Epilepsies (ICD-10: G40), psychogenic non-epileptic seizures (ICD-10: F44–45, F98), and syncope/faint (ICD-10: R55) G40 F44 F45 F98 R55

Interventions

Group 1: This registry study is designed to describe the longitudinal clinical course of patients with epilepsy and psychogenic nonepileptic seizures (PNES). A multidimensional assessment with follow-

Eligibility

Sex/Gender

All

Age

7 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with a diagnosis of epilepsy or psychogenic nonepileptic seizures (PNES) Written informed consent provided by the patient or, where applicable, by the patient's parent(s), legal guardian, or legally authorized representative.

Exclusion criteria

Exclusion criteria: Age <7 years Patients unable to provide informed consent who do not have a legally authorized representative

Design outcomes

Primary

Measure	Time frame
Longitudinal changes in seizure frequency. Data will be collected at 3, 6, 12, 18, and 24 months after enrollment, followed by annual assessments for an additional three years. Data collection will be based on structured interviews and verified against the patients' medical records.	—

Secondary

Measure	Time frame
Quality of Life in Epilepsy Inventory (QOLIE-10P); EuroQol (EQ-5D and EQ-VAS) for the assessment of generic health-related quality of life; WHOQOL-BREF for the assessment of overall quality of life; Beck Depression Inventory-II (BDI-II) for the assessment of depressive symptoms; Multidimensional Fatigue Inventory (MFI); Pittsburgh Sleep Quality Index (PSQI); 13-item Resilience Scale (RS-13); Berlin Social Support Scale (BSSS) for the assessment of perceived social support; and the Treatment Expectation Questionnaire (TEX-Q) for the assessment of treatment expectations. Side effects. Data will be collected at 3, 6, 12, 18, and 24 months after enrollment, followed by annual assessments for an additional three years. Data collection will be based on structured interviews and verified against the patients' medical records.	—

Measure

Time frame

Quality of Life in Epilepsy Inventory (QOLIE-10P); EuroQol (EQ-5D and EQ-VAS) for the assessment of generic health-related quality of life; WHOQOL-BREF for the assessment of overall quality of life; Beck Depression Inventory-II (BDI-II) for the assessment of depressive symptoms; Multidimensional Fatigue Inventory (MFI); Pittsburgh Sleep Quality Index (PSQI); 13-item Resilience Scale (RS-13); Berlin Social Support Scale (BSSS) for the assessment of perceived social support; and the Treatment Expectation Questionnaire (TEX-Q) for the assessment of treatment expectations. Side effects. Data will be collected at 3, 6, 12, 18, and 24 months after enrollment, followed by annual assessments for an additional three years. Data collection will be based on structured interviews and verified against the patients' medical records.

—

Countries

Germany

Contacts

Public ContactYaroslav Winter

Universitätsklinikum des Saarlandes

yaroslav.winter@uks.eu+4968411614107

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Aug 10, 2026